

April 13, 2026

Ntu Singapore Collaborates On Inhaled Treatment For Lung Infections [↗](#)

Ntu Singapore collaborates with Sustech and Lipigon Pharmaceuticals to develop inhaled treatment for severe lung infections, targeting faster patient recovery.



NTU SINGAPORE COLLABORATES ON INHALED TREATMENT FOR LUNG INFECTIONS

NTU Singapore, in collaboration with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB, is spearheading the development of a groundbreaking inhaled treatment targeted at expediting the recovery process for patients grappling with severe lung infections.

The innovative treatment approach is meticulously crafted to address the lingering issue of excessive inflammation within the lungs, a condition that often persists even after the eradication of causative viruses or bacteria from the body.

Addressing a Critical Medical Need

Lung infections, particularly severe cases, pose a significant challenge to healthcare providers worldwide. The aftermath of such infections can result in prolonged inflammation within the lung tissues, leading to complications and delayed recovery for patients. Recognizing this critical medical need, the collaborative efforts of NTU Singapore, SUSTech, and Lipigon Pharmaceuticals AB aim to revolutionize treatment strategies for lung infections.

The Science Behind the Treatment

The inhaled treatment being developed leverages cutting-edge scientific insights to target and mitigate the inflammatory response within the lungs. By specifically focusing on reducing excessive inflammation, the treatment aims to restore normal lung function and accelerate the healing process for patients.

Through a synergistic blend of expertise from NTU Singapore's research capabilities, SUSTech's academic prowess, and Lipigon Pharmaceuticals AB's biotechnological innovations, the collaborative project is poised to introduce a novel therapeutic approach that could potentially transform the landscape of lung infection treatment.

Advantages of Inhaled Treatment

One of the key advantages of an inhaled treatment approach lies in its targeted delivery directly to the site of inflammation within the lungs. By bypassing systemic circulation, inhaled therapies can achieve higher concentrations at the desired location, enhancing efficacy while minimizing potential side effects associated with traditional oral medications.

Furthermore, the convenience and non-invasive nature of inhaled treatments offer a patient-friendly alternative to conventional treatment modalities, potentially improving treatment adherence and overall outcomes for individuals battling severe lung infections.

Future Implications and Clinical Trials

The collaborative efforts between NTU Singapore, SUSTech, and Lipigon Pharmaceuticals AB hold immense promise for the future of lung infection treatment. As the development of the inhaled therapy progresses, the next phase will involve rigorous preclinical studies and eventual clinical trials to evaluate the safety and efficacy of the novel treatment approach.

By adhering to stringent regulatory standards and leveraging the collective expertise of the collaborating institutions, the research team aims to expedite the translation of this innovative therapy from the laboratory to clinical practice, potentially offering a ray of hope for patients grappling with severe lung infections.